1life Healthcare (ONEM) 10-Q13 Aug 202020 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Jul. 31, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Registrant Name	1Life Healthcare Inc
Entity Central Index Key	0001404123
Document Quarterly Report	true
Current Fiscal Year End Date	--12-31
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity File Number	001-39203
Entity Tax Identification Number	76-0707204
Entity Incorporation, State or Country Code	DE
Entity Filer Category	Non-accelerated Filer
Entity Address, Address Line One	One Embarcadero Center
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94111
City Area Code	415
Local Phone Number	814-0927
Document Transition Report	false
Entity Common Stock Shares Outstanding		126,232,766
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ONEM
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 300,675	$ 27,390
Short-term marketable securities	363,736	119,146
Accounts receivable, net	46,211	33,601
Inventories	3,099	3,192
Prepaid expenses and other current assets	20,895	16,708
Total current assets	734,616	200,037
Restricted cash	2,014	1,922
Property and equipment, net	112,922	90,716
Right-of-use assets	130,554	108,046
Intangible assets, net		23
Goodwill	21,301	21,301
Other assets	4,853	8,249
Total assets	1,006,260	430,294
Current liabilities:
Accounts payable	9,822	13,853
Accrued expenses	33,511	24,863
Deferred revenue, current	36,666	27,024
Operating lease liabilities, current	15,090	12,575
Notes payable, current	1,098	3,282
Other current liabilities	1,719	1,884
Total current liabilities	97,906	83,481
Operating lease liabilities, non-current	145,764	120,497
Convertible senior notes	234,617
Redeemable convertible preferred stock warrant liability		7,220
Deferred revenue, non-current	6,409
Other non-current liabilities	3,356	639
Total liabilities	488,052	211,837
Commitments and contingencies (Note 14)
Redeemable convertible preferred stock		402,488
Equity (deficit):
Common stock, $0.001 par value, 1,000,000,000 and 150,000,000 shares authorized as of June 30, 2020 and December 31, 2019, respectively; 126,205,538 and 18,951,416 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	126	19
Additional paid-in capital	863,273	93,945
Accumulated deficit	(345,222)	(281,068)
Accumulated other comprehensive income	31	38
Total stockholders' equity (deficit) attributable to 1Life Healthcare, Inc. stockholders	518,208	(187,066)
Noncontrolling interest		3,035
Total equity (deficit)	518,208	(184,031)
Total liabilities, redeemable convertible preferred stock and equity (deficit)	$ 1,006,260	$ 430,294

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Redeemable convertible preferred stock, par value	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized	0	89,338,425
Redeemable convertible preferred stock, shares issued	0	86,251,669
Redeemable convertible preferred stock, shares outstanding	0	86,251,669
Redeemable convertible preferred stock, aggregate liquidation preference	$ 0	$ 405,585
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	150,000,000
Common stock, shares, issued	126,205,538	18,951,416
Common stock, shares, outstanding	126,205,538	18,951,416

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net revenue	$ 78,000	$ 66,233	$ 156,756	$ 129,243
Operating expenses:
Cost of care, exclusive of depreciation and amortization shown separately below	53,450	39,386	104,999	77,166
Sales and marketing	9,777	8,091	20,933	16,366
General and administrative	38,311	26,970	78,177	49,389
Depreciation and amortization	5,175	3,096	10,388	5,795
Total operating expenses	106,713	77,543	214,497	148,716
Loss from operations	(28,713)	(11,310)	(57,741)	(19,473)
Other income (expense), net:
Interest income	366	1,242	1,400	2,589
Interest expense	(1,976)	(131)	(2,029)	(286)
Change in fair value of redeemable convertible preferred stock warrant liability		(1,273)	(6,560)	(1,336)
Total other income (expense), net	(1,610)	(162)	(7,189)	967
Loss before income taxes	(30,323)	(11,472)	(64,930)	(18,506)
Provision (benefit) for income taxes	(22)	16	(72)	26
Net loss	(30,301)	(11,488)	(64,858)	(18,532)
Less: Net loss attributable to noncontrolling interest		(287)	(704)	(661)
Net loss attributable to 1Life Healthcare, Inc. stockholders	$ (30,301)	$ (11,201)	$ (64,154)	$ (17,871)
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted	$ (0.24)	$ (0.61)	$ (0.61)	$ (0.98)
Weighted average common shares outstanding — basic and diluted	126,150,347	18,365,559	105,517,206	18,285,582

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (30,301)	$ (11,488)	$ (64,858)	$ (18,532)
Other comprehensive loss:
Net unrealized gain (loss) on short-term marketable securities	(51)	36	(7)	67
Comprehensive loss	(30,352)	(11,452)	(64,865)	(18,465)
Less: Comprehensive loss attributable to noncontrolling interests		(287)	(704)	(661)
Comprehensive loss attributable to 1Life Healthcare, Inc. stockholders	$ (30,352)	$ (11,165)	$ (64,161)	$ (17,804)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Cumulative Effect Period of Adoption Adjustment [Member]	IPO	Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred StockIPO	Common Stock	Common StockIPO	Additional Paid-In Capital	Additional Paid-In CapitalIPO	Accumulated Deficit	Accumulated DeficitCumulative Effect Period of Adoption Adjustment [Member]	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. Stockholders'	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. Stockholders'Cumulative Effect Period of Adoption Adjustment [Member]	Total Stockholders' Equity (Deficit) Attributable to 1Life Healthcare, Inc. Stockholders'IPO	Noncontrolling Interests
Beginning balances at Dec. 31, 2018	$ (148,240)	$ (65)				$ 18		$ 76,029		$ (228,449)	$ (65)	$ (14)	$ (152,416)	$ (65)		$ 4,176
Beginning balances, Shares at Dec. 31, 2018				86,251,669
Beginning balances at Dec. 31, 2018				$ 402,488
Beginning balances, Shares at Dec. 31, 2018						18,135,457
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201409Member									us-gaap:AccountingStandardsUpdate201409Member			us-gaap:AccountingStandardsUpdate201409Member
Exercise of stock options	587							587					587
Exercise of stock options, Shares						136,548
Stock-based compensation expense	2,954							2,954					2,954
Net unrealized gain (loss) on short-term marketable securities	31											31	31
Net loss	(7,044)									(6,670)			(6,670)			(374)
Ending balances at Mar. 31, 2019	(151,777)					$ 18		79,570		(235,184)		17	(155,579)			3,802
Ending balances, Shares at Mar. 31, 2019				86,251,669		18,272,005
Ending balances at Mar. 31, 2019				$ 402,488
Beginning balances at Dec. 31, 2018	(148,240)	$ (65)				$ 18		76,029		(228,449)	$ (65)	(14)	(152,416)	$ (65)		4,176
Beginning balances, Shares at Dec. 31, 2018				86,251,669
Beginning balances at Dec. 31, 2018				$ 402,488
Beginning balances, Shares at Dec. 31, 2018						18,135,457
Net unrealized gain (loss) on short-term marketable securities	67
Net loss	(18,532)
Ending balances at Jun. 30, 2019	(159,154)					$ 18		83,645		(246,385)		53	(162,669)			3,515
Ending balances, Shares at Jun. 30, 2019				86,251,669
Ending balances at Jun. 30, 2019				$ 402,488
Ending balances, Shares at Jun. 30, 2019						18,454,411
Beginning balances at Mar. 31, 2019	(151,777)					$ 18		79,570		(235,184)		17	(155,579)			3,802
Beginning balances, Shares at Mar. 31, 2019				86,251,669		18,272,005
Beginning balances at Mar. 31, 2019				$ 402,488
Exercise of stock options	685							685					685
Exercise of stock options, Shares						182,406
Stock-based compensation expense	3,390							3,390					3,390
Net unrealized gain (loss) on short-term marketable securities	36											36	36
Net loss	(11,488)									(11,201)			(11,201)			(287)
Ending balances at Jun. 30, 2019	(159,154)					$ 18		83,645		(246,385)		53	(162,669)			3,515
Ending balances, Shares at Jun. 30, 2019				86,251,669
Ending balances at Jun. 30, 2019				$ 402,488
Ending balances, Shares at Jun. 30, 2019						18,454,411
Beginning balances at Dec. 31, 2019	$ (184,031)					$ 19		93,945		(281,068)		38	(187,066)			3,035
Beginning balances, Shares at Dec. 31, 2019	86,251,669			86,251,669
Beginning balances at Dec. 31, 2019	$ 402,488			$ 402,488
Beginning balances, Shares at Dec. 31, 2019						18,951,416
Exercise of redeemable convertible preferred stock warrant				$ 76
Exercise of redeemable convertible preferred stock warrant, Shares				5,573
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering			$ 402,564		$ (402,564)		$ 86		$ 402,478						$ 402,564
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering, Shares					(86,257,242)		86,257,242
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $23,631			$ 258,119				$ 20		$ 258,099						$ 258,119
Issuance of common stock upon closing of initial public offering, net of issuance costs and underwriting fees of $23,631, Shares							20,125,000
Fair value adjustment to redeemable convertible preferred stock warrants upon conversion into common stock warrants	13,740							13,740					13,740
Exercise of stock options	1,534							1,534					1,534
Exercise of stock options, Shares						293,807
Exercise of common stock warrants	73							73					73
Exercise of common stock warrants, Shares						11,010
Cashless exercise of common stock warrants	1					$ 1							1
Cashless exercise of common stock warrants, Shares						464,297
Stock-based compensation expense	10,325							10,325					10,325
Net unrealized gain (loss) on short-term marketable securities	44											44	44
Net loss	(34,557)									(33,853)			(33,853)			(704)
Ending balances at Mar. 31, 2020	467,812					$ 126		780,194		(314,921)		82	465,481			2,331
Ending balances, Shares at Mar. 31, 2020						126,102,772
Beginning balances at Dec. 31, 2019	$ (184,031)					$ 19		93,945		(281,068)		38	(187,066)			3,035
Beginning balances, Shares at Dec. 31, 2019	86,251,669			86,251,669
Beginning balances at Dec. 31, 2019	$ 402,488			$ 402,488
Beginning balances, Shares at Dec. 31, 2019						18,951,416
Net unrealized gain (loss) on short-term marketable securities	(7)
Net loss	(64,858)
Ending balances at Jun. 30, 2020	$ 518,208					$ 126		863,273		(345,222)		31	518,208
Ending balances, Shares at Jun. 30, 2020	0
Ending balances, Shares at Jun. 30, 2020						126,205,538
Beginning balances at Mar. 31, 2020	$ 467,812					$ 126		780,194		(314,921)		82	465,481			2,331
Beginning balances, Shares at Mar. 31, 2020						126,102,772
Reimbursed secondary offering issuance costs	784							784					784
Exercise of stock options	562							562					562
Exercise of stock options, Shares						102,766
Stock-based compensation expense	8,363							8,363					8,363
Net unrealized gain (loss) on short-term marketable securities	(51)											(51)	(51)
Equity component of convertible senior notes, net of issuance costs of $2,243	73,370							73,370					73,370
VIE deconsolidation	(2,331)															$ (2,331)
Net loss	(30,301)									(30,301)			(30,301)
Ending balances at Jun. 30, 2020	$ 518,208					$ 126		$ 863,273		$ (345,222)		$ 31	$ 518,208
Ending balances, Shares at Jun. 30, 2020	0
Ending balances, Shares at Jun. 30, 2020						126,205,538

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
Stock issuance costs	$ 2,243
IPO
Stock issuance costs		$ 23,631

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (64,858)	$ (18,532)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for bad debts	213
Depreciation and amortization	10,388	5,795
Amortization of debt discount and issuance costs	1,135	50
Accretion of discounts and amortization of premiums on short-term marketable securities, net	(520)	(2,030)
Change in fair value of redeemable convertible preferred stock warrant liability	6,560	1,336
Amortization of right-of-use assets	6,575	4,927
Stock-based compensation	18,688	6,344
Other non-cash items	(10)	33
Changes in operating assets and liabilities:
Accounts receivable, net	(13,591)	(14,954)
Inventories	93	789
Prepaid expenses and other current assets	1,118	(1,226)
Other assets	(250)	(306)
Accounts payable	(2,110)	(671)
Accrued expenses	12,893	823
Deferred revenue	16,051	3,965
Operating lease liabilities	(5,132)	(3,395)
Other liabilities	2,652	2,655
Net cash used in operating activities	(10,105)	(14,397)
Cash flows from investing activities:
Purchases of property and equipment, net	(39,554)	(20,692)
Purchases of short-term marketable securities	(367,367)	(149,973)
Maturities of short-term marketable securities	123,314	208,100
VIE deconsolidation	810
Net cash (used in) provided by investing activities	(284,417)	37,435
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes	316,250
Payment of convertible senior notes issuance costs	8,756
Proceeds from initial public offering	281,750
Payment of underwriting discount and commissions, and offering costs	(21,322)
Proceeds from the exercise of stock options	2,096	1,272
Proceeds from the exercise of redeemable convertible preferred and common stock warrants	110
Repayment of notes payable	(2,200)	(2,200)
Payment of principal portion of finance lease liability	(29)
Net cash provided by (used in) financing activities	567,899	(928)
Net increase in cash, cash equivalents and restricted cash	273,377	22,110
Cash, cash equivalents and restricted cash at beginning of period	29,329	38,656
Cash, cash equivalents and restricted cash at end of period	302,706	60,766
Supplemental disclosure of cash flow information:
Cash paid for interest	76	250
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	3,620	$ 8,317
Issuance costs in connection to convertible senior notes included in accounts payable and accrued expenses	625
Reimbursement of secondary offering costs in prepaid expenses and other current assets	$ 784

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	6 Months Ended
Nature of the Business and Basis of Presentation	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation 1Life Healthcare, Inc. (“1Life”) was incorporated in Delaware on July 25, 2002 and commenced operations in 2004. 1Life’s headquarters are located in San Francisco, California. 1Life has developed a modernized healthcare membership model based on direct consumer enrollment as well as employer sponsorship. 1Life is also an administrative and managerial services company that provides services pursuant to contracts with physician-owned professional corporations (“PCs”) or “One Medical Entities” that provide medical services in-office and virtually. 1Life and the One Medical entities are collectively referred to herein as the “Company” and operate under the brand name One Medical. Initial Public Offering On February 4, 2020, the Company closed its initial public offering (“IPO”) and sold 20,125,000 shares of common stock, including the underwriters’ option to purchase additional shares at the IPO price. The public offering price of the shares sold in the IPO was $ per share. In aggregate, the shares issued in the offering generated $258,119 in net proceeds, which amount is net of $18,314 in underwriters’ discount and commissions, and $5,317 in offering costs. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding were automatically converted into 86,257,242 shares of common stock and all redeemable preferred stock warrants were converted into warrants to purchase 667,668 shares of common stock. In addition, 1,589,798 options held by a named executive officer that were subject to immediate vesting upon the execution of the IPO underwriting agreement vested and accordingly, $3,506 of stock-based compensation expense was recognized. Basis of Presentation The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”), The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited consolidated financial statements as of that date but does not include all of the information and notes required by GAAP for complete financial statements. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2020. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The Company identified a balance sheet misclassification which was not material to the previously issued financial statements. However, the Company has corrected the December 31, 2019 comparative amounts to increase accounts receivable, net and deferred revenue by $3,146 as presented in t he condensed consolidated balance sheet. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Such estimates include revenue recognition, determination of useful lives for property and equipment, intangible assets including goodwill, capitalized internal-use software, allowance for doubtful accounts, valuation of redeemable convertible preferred stock warrant liabilities, self-insurance reserves, valuation of common stock, stock options valuations, convertible senior notes fair value, contingent liabilities and income taxes. Actual results could differ from those estimates. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for doubtful accounts, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”) during the quarter ended June 30, 2020. See Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases. The expected duration of restrictions on the Company’s restricted cash ranges from 1 to 10 years. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: June 30, December 31, June 30, December 31, 2020 2019 2019 2018 Cash and cash equivalents $ 300,675 $ 27,390 $ 58,819 $ 36,692 Restricted cash, current (included in prepaid expenses and other current assets) 17 17 25 25 Restricted cash, non-current 2,014 1,922 1,922 1,939 $ 302,706 $ 29,329 $ 60,766 $ 38,656 Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Cash and cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The table below presents the customers that individually represented 10% or more of the Company’s accounts receivable, net balance as of June 30, 2020 and June 30, December 31, 2020 2019 Customer A * 10 % Customer B 13 % * Customer C 27 % 11 % Customer D 11 % 12 % * Represents percentages below 10% of the Company’s accounts receivable in the period. The table below presents the customers that individually exceeded 10% or more of the Company’s net revenue for the three and six months ended June 30, 2020 and 2019. Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Customer A * 14 % 11 % 14 % Customer B 11 % * 11 % 10 % Customer C 12 % 12 % 12 % 13 % * Represents percentages below 10% of the Company’s net revenue in the period.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. The Company’s significant accounting policies are discussed in Note 2 “Summary of Significant Accounting Policies” in Item 15 of its Form 10-K for the fiscal year ended December 31, 2019. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently Adopted Pronouncements as of June 30, 2020 In August 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2020 In November 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments – Credit Losses , Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates Codification Improvements to Topic 326, Financial Instruments—Credit Losses Codification Improvements to Financial Instruments,

Variable Interest Entities

Variable Interest Entities	6 Months Ended
Variable Interest Entities	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Variable Interest Entities	3. 1Life’s agreements with the PCs generally consist of both Administrative Services Agreements (“ASAs”), which provide for various administrative and management services to be provided by 1Life to the PC, and Succession Agreements, which provide for transition of ownership of the PCs under certain conditions. The ASAs typically provide that the term of the arrangements is ten years with automatic renewal for successive one-year terms, subject to termination by 1Life or the PC in certain specified circumstances. The outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed by 1Life (or the PC in one instance) under the terms of the Succession Agreements or other shareholders who are also subject to the terms of the Succession Agreements. 1Life has the right to receive income as an ongoing administrative fee in an amount that represents fair value of services rendered and has provided all financial support through loans to the PCs. 1Life has exclusive responsibility for the provision of all nonmedical services including facilities, technology and intellectual property required for the day-to-day operation and management of each of the PCs, and makes recommendations to the PC in establishing the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that 1Life has the right to designate a person(s) to purchase the stock of the PCs for a nominal amount in the event of a succession event. Based upon the provisions of these agreements, 1Life determined that the PCs are variable interest entities due to its equity holder having insufficient capital at risk, and 1Life has a variable interest in the PCs. The contractual arrangement to provide management services allows 1Life to direct the economic activities that most significantly affect the PC. Accordingly, 1Life is the primary beneficiary of the PCs and consolidates the PCs under the VIE model. Furthermore, as a direct result of nominal initial equity contributions by the physicians, the financial support 1Life provides to the PCs (e.g. loans) and the provisions of the nominee shareholder succession arrangements described above, the interests held by noncontrolling interest holders lack economic substance and do not provide them with the ability to participate in the residual profits or losses generated by the PCs. Therefore, all income and expenses recognized by the PCs are allocated to 1Life stockholders. The aggregate carrying value of the current assets and liabilities included in the condensed consolidated balance sheets In September 2014, 1Life entered into a joint venture agreement with a healthcare system to jointly operate physician owned primary care offices in a new market. Pursuant to the formation of this joint venture, the healthcare system contributed Effective April 1, 2020, 1Life terminated the joint venture agreement with the healthcare system and transferred its ownership interest in the joint venture to the healthcare system. As a result, the joint venture became a wholly owned subsidiary of the healthcare system. The joint venture was deconsolidated in the condensed consolidated financial statements as of April 1, 2020 and the Company derecognized all assets and liabilities of the joint venture. The Company did not record a gain or loss in association with the deconsolidation as the Company did not retain any noncontrolling interest in the joint venture and no consideration was transferred as a result of the ownership interest transfer to the healthcare system. At the point of deconsolidation, 100% of the net assets were attributable to the noncontrolling interest. The following table shows the balances immediately preceding the deconsolidation of the joint venture that occurred on April 1, 2020 Partially Owned April 1, 2020 Assets Current assets: Cash and cash equivalents $ 810 Accounts receivable, net 768 Prepaid expenses and other current assets 18 Total current assets 1,596 Other assets 19 Property and equipment, net 1,504 Right-of-use assets 1,509 Total assets $ 4,628 Liabilities Current liabilities: Accounts payable and accrued expenses $ 9 Lease liabilities, current 273 Other current liabilities 143 Total current liabilities 425 Lease liabilities, non-current 1,872 Total liabilities $ 2,297 The table below present the assets and liabilities (excluding intercompany balances that are eliminated in consolidation) for the joint venture as of December 31, 2019: Partially Owned December 31, 2019 Assets Current assets: Cash and cash equivalents $ 1,411 Accounts receivable, net 817 Prepaid expenses and other current assets 24 Total current assets 2,252 Other assets 19 Property and equipment, net 1,521 Right-of-use assets 1,553 Total assets $ 5,345 Liabilities Current liabilities: Accounts payable and accrued expenses $ 60 Lease liabilities, current 265 Other current liabilities 57 Total current liabilities 382 Lease liabilities, non-current 1,946 Total liabilities $ 2,328 The condensed consolidated balance sheet as of December 31, 2019 and the condensed consolidated statement of operations for the six months ended June 30, 2020 include the operations of the joint venture through the date of deconsolidation. The condensed consolidated balance sheet as of June 30, 2020 and the condensed consolidated statement of operations for the three months ended June 30, 2020 do not include the operations of the joint venture.

Fair Value

Fair Value	6 Months Ended
Fair Value	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value	4. The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2020 Using: Level 1 Level 2 Level 3 Total Assets: U.S. Treasury obligations $ 334,839 $ - $ - $ 334,839 Commercial paper - 28,897 - 28,897 $ 334,839 $ 28,897 $ - $ 363,736 Fair Value Measurements as of December 31, 2019 Using: Level 1 Level 2 Level 3 Total Assets: U.S. Treasury obligations $ 48,968 $ - $ - $ 48,968 Commercial paper - 70,178 - 70,178 $ 48,968 $ 70,178 $ - $ 119,146 Liabilities: Redeemable convertible preferred stock warrant liability $ - $ - $ 7,220 $ 7,220 $ - $ - $ 7,220 $ 7,220 During the three and six months ended June 30, 2020 and 2019, there were no transfers between Level 1, Level 2 and Level 3. Valuation of Redeemable Convertible Preferred Stock Warrant Liability The redeemable convertible preferred stock warrant liability in the table above relates to redeemable convertible preferred stock warrants issued in connection with certain note payable transactions (See Note 9, “Debt”). The fair value of the redeemable convertible preferred stock warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The warrants were liability-classified due to the contingent redemption features in the underlying preferred stock and were consequently measured at their fair value of $7,220 as of December 31, 2019. Upon the closing of our IPO in the first quarter of 2020, the warrants to purchase shares of redeemable convertible preferred stock became exercisable and were automatically converted to purchase shares of common stock, at which time the Company adjusted the redeemable convertible preferred stock warrant liability to fair value prior to reclassifying the redeemable convertible preferred stock warrant liability to additional paid-in capital. As a result, following the closing of our initial public offering, the warrants will no longer be subject to fair value accounting. Valuation of Convertible Senior Notes The Company has $316,250 aggregate principal amount outstanding of 3.0% convertible senior notes due in 2025 (the “2025 Notes”). Refer to Note 9, “Debt” for further details on the 2025 Notes. As of June 30, 2020, the fair value

Revenue Recognition

Revenue Recognition	6 Months Ended
Revenue Recognition	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue Recognition	5. The following table summarizes the Company’s net revenue by primary source Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Net revenue: Net patient service revenue $ 23,927 $ 34,882 $ 58,013 $ 68,428 Partnership revenue 33,993 18,760 63,448 36,218 Total net patient service and partnership revenue 57,920 53,642 121,461 104,646 Membership revenue 17,680 12,591 32,895 24,597 Grant income 2,400 - 2,400 - Net revenue $ 78,000 $ 66,233 $ 156,756 $ 129,243 Net patient service revenue is primarily generated from commercial third-party payers with which the One Medical entities have established contractual billing arrangements. Net revenue collectible The CARES Act was enacted on March 27, 2020 to provide economic relief to those impacted by the COVID-19 pandemic. The CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant of $2,400 from the Provider Relief Fund administered by the HHS during the three months ended June 30, 2020. Management has concluded that the Company met conditions of the grant funds and has recognized it as Grant income for the three and six months ended June 30, 2020. The Company cannot predict the extent to which it will receive any such additional funds in future periods. During the three and six months ended June 30, 2020, the Company recognized revenue of $15,995 and $17,458, respectively, which was included in the beginning deferred revenue balances as of April 1, 2020 and January 1, 2020, respectively. During the three and six months ended June 30, 2019, the Company recognized revenue of $11,812 and $15,529 , respectively, which was included in the beginning deferred revenue balance as of April 1, 2019 and January 1, 2019, respectively. During the three months ended June 30, 2020, the Company updated its assessment of variable consideration for its existing contracts which resulted in a reduction to net revenue in the amount of $2,451. As of June 30, 2020, a total of $7,151 is recognized within deferred revenue related to variable consideration, of which $6,409 is classified as non-current as it will not be recognized within the next twelve months. The estimate of variable consideration is based on our assessment of historical, current, and forecasted performance. As summarized in the table below, the Company has recorded contract assets and deferred revenue, which result from timing differences between the Company’s performance and the customer’s payment. June 30, December 31, 2020 2019 Balances from contracts with customers: Accounts receivable $ 46,211 $ 33,601 Contract asset (included in prepaid expenses and other current assets) 100 600 Deferred revenue 43,075 27,024 The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of June 30, 2020, is expected to be recognized as follows: Less than Greater or equal to than 12 months 12 months Total As of June 30, 2020 $ 18,274 $ 2,475 $ 20,749

Marketable Securities

Marketable Securities	6 Months Ended
Marketable Securities	Jun. 30, 2020
Marketable Securities [Abstract]
Marketable Securities	6. At June 30, 2020 and December 31, 2019, the Company’s marketable securities classified as available-for-sale were as follows: June 30, 2020 Gross Amortized unrealized cost gains Fair value U.S. Treasury obligations $ 334,800 $ 39 $ 334,839 Commercial paper 28,897 — 28,897 $ 363,697 $ 39 $ 363,736 December 31, 2019 Gross Amortized unrealized cost losses Fair value U.S. Treasury obligations $ 48,930 $ 38 $ 48,968 Commercial paper 70,178 — 70,178 $ 119,108 $ 38 $ 119,146 As of June 30, 2020 and December 31, 2019, all marketable securities have maturity dates within one year.

Property and Equipment, net

Property and Equipment, net	6 Months Ended
Property and Equipment, net	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, net	7. Property and equipment consisted of the following June 30, December 31, 2020 2019 Leasehold improvements $ 103,289 $ 83,018 Computer software, including internal-use software 20,586 16,508 Computer equipment 19,215 16,653 Furniture and fixtures 9,593 7,359 Laboratory equipment 5,201 3,428 Construction in progress 11,426 12,288 169,310 139,254 Less: Accumulated depreciation and amortization (56,388 ) (48,538 ) $ 112,922 $ 90,716 The Company capitalized $2,003 and $4,399 in internal-use software development costs, and recognized depreciation expense related to these assets of $1,101 and $2,121 during the three and six months ended June 30, 2020, respectively. The Company capitalized $1,558 and $2,909 in internal-use software development costs, and recognized depreciation expense related to these assets of $733 and $1,368 during the three and six months ended June 30, 2019, respectively. As of June 30, 2020 and December 31, 2019, the net book value of internal-use software was $11,223 and $8,944, respectively. The Company had disposals in the ordinary course of business of $791 and $891 during the three and six months ended June 30, 2020, respectively, and $593 and $719 during the three and six months ended June 30, 2019. The net loss on disposal was immaterial during the three and six months ended June 30, 2020 and 2019, respectively. Total depreciation and amortization expense related to property and equipment was $5,162 and $10,340, respectively, for the three and six months ended June 30, 2020, and $3,027 and $5,652, respectively, for the three and six months ended June 30, 2019. All long-lived assets are maintained in the United States.

Leases

Leases	6 Months Ended
Leases	Jun. 30, 2020
Leases [Abstract]
Leases	8. Leases Most leases contain clauses for renewal at the Company’s option with renewal terms that generally extend the lease term from 1 to 5 years. Certain lease agreements contain options to terminate the lease before maturity. The Company does not have any lease contracts with the option to purchase as of June 30, 2020. The Company’s lease agreements do not contain any significant residual value guarantees or material restrictive covenants imposed by the leases. Certain of the Company’s furniture and fixtures and lab equipment are held under finance leases. These lease-related assets are included in property and equipment, net in the condensed consolidated balance sheets and are immaterial as of June 30, 2020. The components of operating lease costs were as follows: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Operating lease costs $ 6,355 $ 12,315 Variable lease costs 1,013 2,029 Total lease costs $ 7,368 $ 14,344 Other information related to leases was as follows: Supplemental Cash Flow Information Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 5,920 $ 11,358 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 7,031 $ 30,638 Lease Term and Discount Rate As of June 30, 2020 Weighted-average remaining lease term (in years) 8.60 Weighted-average discount rate 7.73 % At the lease commencement date, the discount rate implicit in the lease is used to discount the lease liability if readily determinable. If not readily determinable or leases do not contain an implicit rate, the Company’s incremental borrowing rate is used as the discount rate. Management determines the appropriate incremental borrowing rates for each of its leases based on the remaining lease term at lease commencement. Future minimum lease payments As of June 30, 2020 Remainder of 2020 $ 13,339 2021 27,574 2022 26,045 2023 25,156 2024 24,746 Thereafter 108,388 Total lease payments 225,248 Less: interest (64,394 ) Total lease liabilities $ 160,854

Debt

Debt	6 Months Ended
Debt	Jun. 30, 2020
Debt Disclosure [Abstract]
Debt	9 . Debt Term Notes In January 2013, the Company entered into a loan and security agreement with an institutional lender and with subsequent amendments for borrowings of $11,000 at Borrowings under the LSA are secured by substantially all of the Company’s properties, rights and assets, excluding intellectual property. The LSA contains certain customary restrictive covenants that limit the Company’s ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, amend the ASAs and transfer or dispose of assets. In addition, the Company must maintain one of two financial covenants: (i) a liquidity ratio of not less than 1.50 to 1.00 or (ii) a fixed charge coverage ratio of not less than 1.25 to 1.00. The Company is in compliance The Company recorded aggregate interest expense of $28 and $78, respectively, for the three and six months ended June 30, 2020, and $131 and $286, respectively, for the three and six months ended June 30, 2019. The non-cash interest expense related to the accretion of debt discounts for common and redeemable convertible preferred stock warrants included in the aggregate interest expense for the three and six months ended June 30, 2020 and 2019 was immaterial. The Company’s annual effective interest rate was 5.6% and 6.1%, respectively, for the three and six months ended June 30, 2020, and 7.3% and 7.3%, respectively, for the three and six months ended June 30, 2019. The Company made aggregate principal payments of $1,100 and $2,200, respectively, during the three and six months ended June 30, 2020 and, $1,100 and $2,200, respectively, during the three and six months ended June 30, 2019. All future minimum payments on notes payable will mature in 2020. As a result of the debt discount and the final payment fees, the future minimum payments of the outstanding notes payable balance do not equal the current notes payable in the condensed consolidated balance sheets. Convertible Senior Notes In May 2020, the Company issued and sold $275,000 aggregate principal amount of 3.0% convertible senior notes due 2025 in a private offering exempt from the registration requirements of the Securities Act of 1933, and in June 2020, the Company issued an additional $41,250 aggregate principal amount of such notes pursuant to the exercise in full of the over-allotment option by the initial purchasers of the notes (the “2025 Notes”). The 2025 Notes are unsecured obligations and bear interest at a fixed rate of 3.0% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, commencing on December 15, 2020. The 2025 Notes will mature on June 15, 2025, unless earlier converted, redeemed or repurchased. The total net proceeds from the debt offering, after deducting the initial purchasers’ commissions and other issuance costs, were $306,868 Each $1 principal amount of the 2025 Notes will initially be convertible into 22.5052 shares of the Company’s common stock, which is equivalent to an initial conversion price of $44.43 per share, subject to adjustment upon the occurrence of specified events but not for any accrued and unpaid interest. Holders may convert the 2025 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined below) per $1 principal amount of the 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. It is the Company’s current intent to settle conversions through combination settlement comprising of cash and equity On or after March 15, 2025 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their 2025 Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election and in accordance with the terms of the indenture governing the 2025 Notes. If the Company satisfies its conversion obligation solely in cash or through payment and delivery, as the case may be, of a combination of cash and shares of the Company’s common stock, the amount of cash and shares of common stock, if any, due upon conversion will be based on a daily conversion value calculated on a proportionate basis for each trading day in a 40 trading day observation period. In addition, following certain corporate events that occur prior to the maturity date or if the Company delivers a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2025 Notes in connection with such a corporate event or notice of redemption, as the case may be. If the Company undergoes a fundamental change prior to the maturity date, holders of the 2025 Notes may require the Company to repurchase for cash all or any portion of their notes at a repurchase price equal to 100% of the principal amount of the 2025 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date In addition, if specific corporate events occur prior to the applicable maturity date, the Company will increase the conversion rate for a holder who elects to convert their 2025 Notes The Company may not redeem the 2025 Notes prior to June 20, 2023. The Company may redeem for cash all or any portion of the 2025 Notes, at the Company’s option, on or after June 20, 2023 and prior to March 15, 2025, if the last reported sale price of the Company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the 2025 Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the notes. In accounting for the issuance of the 2025 Notes, the Company separated the 2025 Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar debt instrument that does not have an associated convertible feature. As of the issuance date of the 2025 Notes, the liability component was initially measured at $240,637. The carrying amount of the equity component representing the conversion option was $75,613 and was determined by deducting the fair value of the liability component from the par value of the 2025 Notes. The equity component was recorded in additional paid-in capital and is not remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the liability component over its carrying amount (debt discount) is amortized to interest expense over the contractual term of the 2025 Notes at an effective interest rate of 9.68%. In accounting for the debt issuance costs of $9,382 related to the 2025 Notes, the Company allocated the total amount incurred to the liability and equity components of the 2025 Notes based on their relative values. Issuance costs attributable to the liability component were $7,139 and will be amortized to interest expense using the effective interest method over the contractual terms of the 2025 Notes. Issuance costs attributable to the equity component of $2,243 were netted with the equity component in additional paid-in capital. The net carrying amount of the liability component of the 2025 Notes was as follows: June 30, 2020 Principal $ 316,250 Unamortized debt discount (74,573 ) Unamortized issuance costs (7,060 ) Net carrying amount 234,617 The net carrying amount of the equity component of the 2025 Notes was as follows: June 30, 2020 Debt discount related to value of conversion option $ 75,613 Issuance costs (2,243 ) Net carrying amount 73,370 The following table sets forth the interest expense recognized related to the 2025 Notes: Three and Six Months Ended June 30, 2020 Contractual interest expense $ 826 Amortization of debt discount 1,041 Amortization of issuance costs 79 Total interest expense related to the 2025 Notes 1,946

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	6 Months Ended
Redeemable Convertible Preferred Stock	Jun. 30, 2020
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	1 0 . Redeemable Convertible Preferred Stock As of December 31, 2019, there were warrants to purchase 100,000 shares of Series C redeemable convertible preferred stock, 250,000 redeemable convertible preferred stock, 99,280 shares of redeemable convertible preferred stock, and 223,961 shares of redeemable convertible preferred stock outstanding. Warrants to purchase 5,573 shares of Series G redeemable convertible preferred stock were converted to preferred stock prior to the closing of the IPO. all warrants were converted into warrants to purchase 667,668 shares of common stock. redeemable convertible preferred stock then outstanding were automatically converted into 86,257,242 shares of common stock.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation Stock Option Plan The Company has the following stock-based compensation plans: 2007 Equity Incentive Plan (the “2007 Plan”), the 2017 Equity Incentive Plan (the “2017 Plan”), and the 2020 Equity Incentive Plan (the "2020 Plan", and, together with the 2007 Plan and the 2017 Plan, the "Plans"). In January 2020, the Company’s stockholders approved the Company’s 2020 Equity Incentive Plan, which took effect upon the execution of the underwriting agreement for the Company’s IPO in January 2020. The 2020 Plan is intended as the successor to and continuation of the 2007 Plan and the 2017 Plan. No additional stock awards will be granted under these plans. The number of shares issuable under the Plans is adjusted for capitalization changes, forfeitures, expirations and certain share reacquisitions. The Plan provides for the grants of incentive stock options ("ISOs"), nonstatutory stock options ("NSOs"), restricted stock awards, and restricted stock unit awards ("RSUs"). ISOs may be granted only to employees, including officers. All other awards may be granted to employees, including officers, non-employee directors and consultants. The 2020 Plan provides that grants of ISOs will be made at no less than the estimated fair value of common stock, as determined by the Board of Directors, at the date of grant. . At June 30, 2020, 18,604,144 shares were available for future grants. 2020 Employee Stock Purchase Plan In January 2020, the Company’s stockholders approved the 2020 Employee Stock Purchase Plan (“ESPP”) The stock-based compensation expense recognized for the ESPP was $597 and $1,006 during the three and six months ended June 30, 2020 Stock Option Activity The following table summarizes stock option activity under the 2020 Plan: Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term (Years) Value Outstanding as of December 31, 2019 27,806,309 $ 5.97 7.76 $ 207,956 Granted 375,200 22.15 Exercised (396,573 ) 5.29 Cancelled (148,777 ) 8.69 Outstanding as of June 30, 2020 27,636,159 $ 6.19 7.04 $ 832,784 Options exercisable as of June 30, 2020 14,862,415 $ 4.46 5.86 $ 189,208 Options vested and expected to vest as of June 30, 2020 24,109,807 $ 5.78 6.81 $ 736,237 The fair value of options granted RSU Activity The following table summarizes the RSU activity Number of Grant Date Shares Fair Value Unvested and outstanding as of December 31, 2019 - $ - Granted 1,334,628 19.95 Vested - - Canceled and forfeited (14,993 ) 20.79 Unvested and outstanding as of June 30, 2020 1,319,635 $ 19.94 Stock-Based Compensation Expense Total stock-based compensation expense Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Sales and marketing $ 668 $ 151 $ 1,268 $ 462 General and administrative 7,695 3,239 17,420 5,882 $ 8,363 $ 3,390 $ 18,688 $ 6,344 Common Stock In June 2020, the Company completed a secondary offering in which certain stockholders sold 8,300,000 shares of common stock at an offering price of $31.00 per share. The selling stockholders received all of the net proceeds from the sale of shares in this offering. The Company did not sell any shares or receive any proceeds in this secondary offering.

Income Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	1 2 . The Company recorded an income tax benefit of $22 and $72, respectively, for the three and six months ended June 30, 2020, and an income tax provision of $16 and $26, respectively, for the three and six months ended June 30, 2019. This represents an effective tax rate for the respective periods of .075% and .124%, respectively, for the three and six months ended June 30, 2020, and (.137%), and (.141%), respectively, for the three and six months ended June 30, 2019. The Company has historically been in an overall loss position and is only subject to state minimum taxes. The Company maintains a full valuation allowance for all of its deferred tax assets. The effective tax rate differs in 2020 from the federal statutory rate due to recognition of benefits of the CARES Act and the change in need for a valuation allowance. The effective tax rate differs in 2019 due to the change in need for a valuation allowance and state minimum taxes. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act was enacted on March 27, 2020

Net Loss Per Share

Net Loss Per Share	6 Months Ended
Net Loss Per Share	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	1 3 . Net Loss Per Share Net Loss Per Share Attributable to 1Life Healthcare, Inc. Stockholders Basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders’ was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Numerator: Net loss $ (30,301 ) $ (11,488 ) $ (64,858 ) $ (18,532 ) Less: Net loss attributable to noncontrolling interest - (287 ) (704 ) (661 ) Net loss attributable to 1Life Healthcare, Inc. stockholders' $ (30,301 ) $ (11,201 ) $ (64,154 ) $ (17,871 ) Denominator: Weighted average common shares outstanding— basic and diluted 126,150,347 18,365,559 105,517,206 18,285,582 Net loss per share attributable to 1Life Healthcare, Inc. stockholders'— basic and diluted $ (0.24 ) $ (0.61 ) $ (0.61 ) $ (0.98 ) The Company’s potentially dilutive securities, which include stock options, unvested RSUs, 2025 Notes, redeemable convertible preferred stock and warrants to purchase shares of redeemable convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders’ is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders’ for the periods indicated because including them would have had an anti-dilutive effect: As of June 30, 2020 2019 Options to purchase common stock 27,636,159 23,234,596 Warrants to purchase common stock 161,825 - Unvested restricted stock 1,319,635 - Redeemable convertible preferred stock (as converted to common stock) - 86,251,669 Warrants to purchase redeemable convertible preferred stock (as converted to common stock) - 673,241 29,117,619 110,159,506 As the Company expects to settle the principal amount of the 2025 Notes in cash and any excess in cash or shares of the Company’s common stock

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	1 4 . Commitments and Contingencies Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its Board of Directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. As of June 30, 2020 and December 31, 2019, the Company has not incurred any material costs as a result of such indemnifications. Legal Matters In May 2018, a class action complaint was filed by two former members against the Company in the Superior Court of California for the County of San Francisco, or the Court, alleging that the Company made certain misrepresentations resulting in them paying the Annual Membership Fee, or AMF in violation of California’s Consumers Legal Remedies Act, California’s False Advertising Law and California’s Unfair Competition Law, and seeking damages and injunctive relief. In September 2018, the Company filed a motion to compel the plaintiffs to individually arbitrate their claims, which motion was granted as to one plaintiff and denied as to the other. The Company is appealing the denial of its motion to compel arbitration and filed its appellate brief in November 2019. Appellate proceedings are delayed due to COVID-related court shutdowns. An arbitrator conducted arbitration between the Company and the plaintiff ordered to arbitration, and in June 2020, issued a decision that the arbitration agreement is unenforceable against the plaintiff. The Company filed its challenge to the arbitrator’s decision in August 2020. In addition, from time to time, the Company has been and may be involved in various legal proceedings arising in the ordinary course of business. The Company currently believes that the outcome of these legal proceedings, either individually or in the aggregate, will not have a material effect on its condensed consolidated financial position, results of operations or cash flows. Sales and Use Tax During 2017 and 2018, a state jurisdiction engaged in an audit of 1Life’s sales and use tax records applicable to that jurisdiction from March 2011 through February 2017. As of June 30, 2020, the Company estimated a probable loss from the audit and recorded the estimate in accrued expenses related to one aspect of the finding, including interest and penalties. The Company disputes the other finding representing the majority of the state’s proposed audit change and has filed a notice of appeal. At this time, the Company believes it has a compelling basis to dispute the audit finding and it is not able to estimate the amount of loss or range of loss, if any, related to this matter.

Related Party Transactions

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	1 5 . Related Party Transactions Certain of the Company’s investors are also customers of the Company. The Company recognized revenue under contractual obligations from such customers of $155 and $201, respectively, for the three and six months ended June 30, 2020, and $38 and $76, respectively, for the three and six months ended June 30, 2019. The Company had outstanding receivable balances of $210 and $2,344 from such customers as of June 30, 2020 and December 31, 2019, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2020
Accounting Policies [Abstract]
Initial Public Offering	Initial Public Offering On February 4, 2020, the Company closed its initial public offering (“IPO”) and sold 20,125,000 shares of common stock, including the underwriters’ option to purchase additional shares at the IPO price. The public offering price of the shares sold in the IPO was $ per share. In aggregate, the shares issued in the offering generated $258,119 in net proceeds, which amount is net of $18,314 in underwriters’ discount and commissions, and $5,317 in offering costs. Upon the closing of the IPO, all shares of redeemable convertible preferred stock then outstanding were automatically converted into 86,257,242 shares of common stock and all redeemable preferred stock warrants were converted into warrants to purchase 667,668 shares of common stock. In addition, 1,589,798 options held by a named executive officer that were subject to immediate vesting upon the execution of the IPO underwriting agreement vested and accordingly, $3,506 of stock-based compensation expense was recognized.
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”), The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited consolidated financial statements as of that date but does not include all of the information and notes required by GAAP for complete financial statements. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the related notes thereto as of and for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 27, 2020. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The Company identified a balance sheet misclassification which was not material to the previously issued financial statements. However, the Company has corrected the December 31, 2019 comparative amounts to increase accounts receivable, net and deferred revenue by $3,146 as presented in t he condensed consolidated balance sheet.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Such estimates include revenue recognition, determination of useful lives for property and equipment, intangible assets including goodwill, capitalized internal-use software, allowance for doubtful accounts, valuation of redeemable convertible preferred stock warrant liabilities, self-insurance reserves, valuation of common stock, stock options valuations, convertible senior notes fair value, contingent liabilities and income taxes. Actual results could differ from those estimates. Due to the COVID-19 global pandemic, the global economy and financial markets have been disrupted and there is a significant amount of uncertainty about the length and severity of the consequences caused by the pandemic. The Company has considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or an adjustment to the carrying value of its assets or liabilities. The accounting estimates and other matters assessed include, but were not limited to, allowance for doubtful accounts, goodwill and other long-lived assets, and revenue recognition. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020. Intended to provide economic relief to those impacted by the COVID-19 pandemic, the CARES Act includes various tax and lending provisions, among others. Under the CARES Act, the Company received an income grant from the Provider Relief Fund administered by the Department of Health and Human Services (“HHS”) during the quarter ended June 30, 2020. See
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all short-term, highly liquid investments purchased with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States. Cash and cash equivalents consisted of cash on deposit, investments in money market funds and commercial paper. Restricted cash represents cash held under letters of credit for various leases. The expected duration of restrictions on the Company’s restricted cash ranges from 1 to 10 years. The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: June 30, December 31, June 30, December 31, 2020 2019 2019 2018 Cash and cash equivalents $ 300,675 $ 27,390 $ 58,819 $ 36,692 Restricted cash, current (included in prepaid expenses and other current assets) 17 17 25 25 Restricted cash, non-current 2,014 1,922 1,922 1,939 $ 302,706 $ 29,329 $ 60,766 $ 38,656
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers Financial instruments that potentially subject the company to concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Cash and cash equivalents are invested in highly rated money market funds and commercial paper. The Company’s cash balances with individual banking institutions might be in excess of federally insured limits. The Company’s marketable securities are invested in U.S. Treasury obligations and commercial paper. The Company is not exposed to any significant concentrations of credit risk from these financial instruments. The table below presents the customers that individually represented 10% or more of the Company’s accounts receivable, net balance as of June 30, 2020 and June 30, December 31, 2020 2019 Customer A * 10 % Customer B 13 % * Customer C 27 % 11 % Customer D 11 % 12 % * Represents percentages below 10% of the Company’s accounts receivable in the period. The table below presents the customers that individually exceeded 10% or more of the Company’s net revenue for the three and six months ended June 30, 2020 and 2019. Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Customer A * 14 % 11 % 14 % Customer B 11 % * 11 % 10 % Customer C 12 % 12 % 12 % 13 % * Represents percentages below 10% of the Company’s net revenue in the period.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently Adopted Pronouncements as of June 30, 2020 In August 2018, the FASB issued Accounting Standards Update (“ASU”) 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception Recently Issued Accounting Pronouncements Not Yet Adopted as of June 30, 2020 In November 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments – Credit Losses , Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments Financial Instruments – Credit Losses (Topic 326): Targeted Transition Relief Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates Codification Improvements to Topic 326, Financial Instruments—Credit Losses Codification Improvements to Financial Instruments,

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation (Tables)	6 Months Ended
Nature of the Business and Basis of Presentation (Tables)	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Reconciliation of Cash, Cash Equivalents and Restricted Cash	The reconciliation of cash, cash equivalents and restricted cash reported within the applicable balance sheet line items that sum to the total of the same such amount shown in the condensed consolidated statements of cash flows is as follows: June 30, December 31, June 30, December 31, 2020 2019 2019 2018 Cash and cash equivalents $ 300,675 $ 27,390 $ 58,819 $ 36,692 Restricted cash, current (included in prepaid expenses and other current assets) 17 17 25 25 Restricted cash, non-current 2,014 1,922 1,922 1,939 $ 302,706 $ 29,329 $ 60,766 $ 38,656
Summary of Customers Representing 10% or More of Accounts Receivables	The table below presents the customers that individually represented 10% or more of the Company’s accounts receivable, net balance as of June 30, 2020 and June 30, December 31, 2020 2019 Customer A * 10 % Customer B 13 % * Customer C 27 % 11 % Customer D 11 % 12 % * Represents percentages below 10% of the Company’s accounts receivable in the period.
Summary of Customers Representing 10% or More of Net Revenue	The table below presents the customers that individually exceeded 10% or more of the Company’s net revenue for the three and six months ended June 30, 2020 and 2019. Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Customer A * 14 % 11 % 14 % Customer B 11 % * 11 % 10 % Customer C 12 % 12 % 12 % 13 % * Represents percentages below 10% of the Company’s net revenue in the period.

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	6 Months Ended
Variable Interest Entities (Tables)	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Deconsolidation of Joint Venture	At the point of deconsolidation, 100% of the net assets were attributable to the noncontrolling interest. The following table shows the balances immediately preceding the deconsolidation of the joint venture that occurred on April 1, 2020 Partially Owned April 1, 2020 Assets Current assets: Cash and cash equivalents $ 810 Accounts receivable, net 768 Prepaid expenses and other current assets 18 Total current assets 1,596 Other assets 19 Property and equipment, net 1,504 Right-of-use assets 1,509 Total assets $ 4,628 Liabilities Current liabilities: Accounts payable and accrued expenses $ 9 Lease liabilities, current 273 Other current liabilities 143 Total current liabilities 425 Lease liabilities, non-current 1,872 Total liabilities $ 2,297
Assets and Liabilities Excluding Intercompany Balances are Eliminated in Consolidated for Joint Ventures	The table below present the assets and liabilities (excluding intercompany balances that are eliminated in consolidation) for the joint venture as of December 31, 2019: Partially Owned December 31, 2019 Assets Current assets: Cash and cash equivalents $ 1,411 Accounts receivable, net 817 Prepaid expenses and other current assets 24 Total current assets 2,252 Other assets 19 Property and equipment, net 1,521 Right-of-use assets 1,553 Total assets $ 5,345 Liabilities Current liabilities: Accounts payable and accrued expenses $ 60 Lease liabilities, current 265 Other current liabilities 57 Total current liabilities 382 Lease liabilities, non-current 1,946 Total liabilities $ 2,328

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
Fair Value (Tables)	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements as of June 30, 2020 Using: Level 1 Level 2 Level 3 Total Assets: U.S. Treasury obligations $ 334,839 $ - $ - $ 334,839 Commercial paper - 28,897 - 28,897 $ 334,839 $ 28,897 $ - $ 363,736 Fair Value Measurements as of December 31, 2019 Using: Level 1 Level 2 Level 3 Total Assets: U.S. Treasury obligations $ 48,968 $ - $ - $ 48,968 Commercial paper - 70,178 - 70,178 $ 48,968 $ 70,178 $ - $ 119,146 Liabilities: Redeemable convertible preferred stock warrant liability $ - $ - $ 7,220 $ 7,220 $ - $ - $ 7,220 $ 7,220

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
Revenue Recognition (Tables)	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Summary of Net Revenue	The following table summarizes the Company’s net revenue by primary source Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Net revenue: Net patient service revenue $ 23,927 $ 34,882 $ 58,013 $ 68,428 Partnership revenue 33,993 18,760 63,448 36,218 Total net patient service and partnership revenue 57,920 53,642 121,461 104,646 Membership revenue 17,680 12,591 32,895 24,597 Grant income 2,400 - 2,400 - Net revenue $ 78,000 $ 66,233 $ 156,756 $ 129,243
Schedule of Contract Assets and Deferred Revenue	As summarized in the table below, the Company has recorded contract assets and deferred revenue, which result from timing differences between the Company’s performance and the customer’s payment. June 30, December 31, 2020 2019 Balances from contracts with customers: Accounts receivable $ 46,211 $ 33,601 Contract asset (included in prepaid expenses and other current assets) 100 600 Deferred revenue 43,075 27,024
Schedule of Remaining Performance Obligation	The Company does not disclose the value of remaining performance obligations for (i) contracts with an original contract term of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice when that amount corresponds directly with the value of services performed, and (iii) variable consideration allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied distinct service that forms part of a single performance obligation. For those contracts that do not meet the above criteria, the Company’s remaining performance obligation as of June 30, 2020, is expected to be recognized as follows: Less than Greater or equal to than 12 months 12 months Total As of June 30, 2020 $ 18,274 $ 2,475 $ 20,749

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
Marketable Securities (Tables)	Jun. 30, 2020
Marketable Securities [Abstract]
Summary of Marketable Securities Classified as Available for Sale	At June 30, 2020 and December 31, 2019, the Company’s marketable securities classified as available-for-sale were as follows: June 30, 2020 Gross Amortized unrealized cost gains Fair value U.S. Treasury obligations $ 334,800 $ 39 $ 334,839 Commercial paper 28,897 — 28,897 $ 363,697 $ 39 $ 363,736 December 31, 2019 Gross Amortized unrealized cost losses Fair value U.S. Treasury obligations $ 48,930 $ 38 $ 48,968 Commercial paper 70,178 — 70,178 $ 119,108 $ 38 $ 119,146

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	6 Months Ended
Property and Equipment, net (Tables)	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consisted of the following June 30, December 31, 2020 2019 Leasehold improvements $ 103,289 $ 83,018 Computer software, including internal-use software 20,586 16,508 Computer equipment 19,215 16,653 Furniture and fixtures 9,593 7,359 Laboratory equipment 5,201 3,428 Construction in progress 11,426 12,288 169,310 139,254 Less: Accumulated depreciation and amortization (56,388 ) (48,538 ) $ 112,922 $ 90,716

Leases (Tables)

Leases (Tables)	6 Months Ended
Leases (Tables)	Jun. 30, 2020
Leases [Abstract]
Components of Operating Lease Costs	The components of operating lease costs were as follows: Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Operating lease costs $ 6,355 $ 12,315 Variable lease costs 1,013 2,029 Total lease costs $ 7,368 $ 14,344
Supplemental Cash Flow Information	Supplemental Cash Flow Information Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 5,920 $ 11,358 Non-cash leases activity: Right-of-use lease assets obtained in exchange for new operating lease liabilities $ 7,031 $ 30,638
Lease Term and Discount Rate	Lease Term and Discount Rate As of June 30, 2020 Weighted-average remaining lease term (in years) 8.60 Weighted-average discount rate 7.73 %
Future Minimum Lease Payments Under Non-cancellable Operating Leases	Future minimum lease payments As of June 30, 2020 Remainder of 2020 $ 13,339 2021 27,574 2022 26,045 2023 25,156 2024 24,746 Thereafter 108,388 Total lease payments 225,248 Less: interest (64,394 ) Total lease liabilities $ 160,854

Debt (Tables)

Debt (Tables)	6 Months Ended
Debt (Tables)	Jun. 30, 2020
Summary of Interest Expense Recognized Related to Convertible Senior Notes	The following table sets forth the interest expense recognized related to the 2025 Notes: Three and Six Months Ended June 30, 2020 Contractual interest expense $ 826 Amortization of debt discount 1,041 Amortization of issuance costs 79 Total interest expense related to the 2025 Notes 1,946
Debt Liability Component
Net Carrying Amount of Convertible Senior Notes	The net carrying amount of the liability component of the 2025 Notes was as follows: June 30, 2020 Principal $ 316,250 Unamortized debt discount (74,573 ) Unamortized issuance costs (7,060 ) Net carrying amount 234,617
Debt Equity Component
Net Carrying Amount of Convertible Senior Notes	The net carrying amount of the equity component of the 2025 Notes was as follows: June 30, 2020 Debt discount related to value of conversion option $ 75,613 Issuance costs (2,243 ) Net carrying amount 73,370

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
Stock-Based Compensation (Tables)	Jun. 30, 2020
Summary of Stock-Based Compensation Expense	Stock-based compensation expense was classified in the condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Sales and marketing $ 668 $ 151 $ 1,268 $ 462 General and administrative 7,695 3,239 17,420 5,882 $ 8,363 $ 3,390 $ 18,688 $ 6,344
2020 Plan
Summary of Stock Option Activity	The following table summarizes stock option activity under the 2020 Plan: Weighted- Weighted- Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Term (Years) Value Outstanding as of December 31, 2019 27,806,309 $ 5.97 7.76 $ 207,956 Granted 375,200 22.15 Exercised (396,573 ) 5.29 Cancelled (148,777 ) 8.69 Outstanding as of June 30, 2020 27,636,159 $ 6.19 7.04 $ 832,784 Options exercisable as of June 30, 2020 14,862,415 $ 4.46 5.86 $ 189,208 Options vested and expected to vest as of June 30, 2020 24,109,807 $ 5.78 6.81 $ 736,237
Summary of RSU Activity	The following table summarizes the RSU activity Number of Grant Date Shares Fair Value Unvested and outstanding as of December 31, 2019 - $ - Granted 1,334,628 19.95 Vested - - Canceled and forfeited (14,993 ) 20.79 Unvested and outstanding as of June 30, 2020 1,319,635 $ 19.94

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
Net Loss Per Share (Tables)	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders’ was calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Numerator: Net loss $ (30,301 ) $ (11,488 ) $ (64,858 ) $ (18,532 ) Less: Net loss attributable to noncontrolling interest - (287 ) (704 ) (661 ) Net loss attributable to 1Life Healthcare, Inc. stockholders' $ (30,301 ) $ (11,201 ) $ (64,154 ) $ (17,871 ) Denominator: Weighted average common shares outstanding— basic and diluted 126,150,347 18,365,559 105,517,206 18,285,582 Net loss per share attributable to 1Life Healthcare, Inc. stockholders'— basic and diluted $ (0.24 ) $ (0.61 ) $ (0.61 ) $ (0.98 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to 1Life Healthcare, Inc. stockholders’ for the periods indicated because including them would have had an anti-dilutive effect: As of June 30, 2020 2019 Options to purchase common stock 27,636,159 23,234,596 Warrants to purchase common stock 161,825 - Unvested restricted stock 1,319,635 - Redeemable convertible preferred stock (as converted to common stock) - 86,251,669 Warrants to purchase redeemable convertible preferred stock (as converted to common stock) - 673,241 29,117,619 110,159,506

Nature of the Business and Ba_3

Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 04, 2020	Jun. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Accounts receivable, net		$ 46,211	$ 33,601
Deferred revenue, current		$ 36,666	27,024
IPO
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Initial public offering closing date	Feb. 4, 2020
Stock issued during period, shares, new issues	20,125,000
Public offering price of the shares sold in the IPO	$ 14
Net proceeds from shares issued in the offering, net of underwriting discount and offering costs	$ 258,119
Underwriters’ discount	18,314
Deferred offering costs capitalized	$ 5,317
Redeemable convertible preferred stock converted into shares of common stock	86,257,242
Unrecognized stock-based compensation expense	$ 3,506
IPO \| Warrants to Purchase Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of warrants issued	667,668
IPO \| Stock Options
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stock options granted	1,589,798
Restatement Adjustment
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Accounts receivable, net			3,146
Deferred revenue, current			$ 3,146

Nature of the Business and Ba_4

Nature of the Business and Basis of Presentation - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash And Cash Equivalents [Abstract]
Cash and cash equivalents	$ 300,675	$ 27,390	$ 58,819	$ 36,692
Restricted cash, current (included in prepaid expenses and other current assets)	17	17	25	25
Restricted cash	2,014	1,922	1,922	1,939
Cash, cash equivalents and restricted cash	$ 302,706	$ 29,329	$ 60,766	$ 38,656

Nature of the Business and Ba_5

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Accounts Receivables (Details) - Customer Concentration Risk - Accounts Receivable, Net	6 Months Ended		12 Months Ended
	Jun. 30, 2020		Dec. 31, 2019
Customer A
Product Information [Line Items]
Concentration risk, percentage		[1]	10.00%
Customer B
Product Information [Line Items]
Concentration risk, percentage	13.00%			[1]
Customer C
Product Information [Line Items]
Concentration risk, percentage	27.00%		11.00%
Customer D
Product Information [Line Items]
Concentration risk, percentage	11.00%		12.00%

[1]	Represents percentages below 10% of the Company’s accounts receivable in the period.

Nature of the Business and Ba_6

Nature of the Business and Basis of Presentation - Summary of Customers Representing 10% or More of Net Revenue (Details) - Customer Concentration Risk - Net Revenue	3 Months Ended				6 Months Ended
	Jun. 30, 2020		Jun. 30, 2019		Jun. 30, 2020	Jun. 30, 2019
Customer A
Product Information [Line Items]
Concentration risk, percentage		[1]	14.00%		11.00%	14.00%
Customer B
Product Information [Line Items]
Concentration risk, percentage	11.00%			[1]	11.00%	10.00%
Customer C
Product Information [Line Items]
Concentration risk, percentage	12.00%		12.00%		12.00%	13.00%

[1]	Represents percentages below 10% of the Company’s net revenue in the period.

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Sep. 30, 2014	Jun. 30, 2020	Apr. 01, 2020	Dec. 31, 2019
Variable Interest Entity [Line Items]
Current assets		$ 734,616		$ 200,037
Current liabilities		97,906		83,481
Healthcare System \| 1Life Healthcare Incorporation
Variable Interest Entity [Line Items]
Minority interest entity interest percentage			100.00%
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Cash received in noncontrolling interests		10,000
Variable Interest Entity, Primary Beneficiary \| Healthcare System \| 1Life Healthcare Incorporation
Variable Interest Entity [Line Items]
Payments to acquire interest in joint venture	$ 10,000
Minority interest entity interest percentage	56.90%
Variable Interest Entity, Primary Beneficiary \| 1Life Management Expertise \| 1Life Healthcare Incorporation
Variable Interest Entity [Line Items]
Variable interest entity interest percentage	43.10%
Variable Interest Entity, Primary Beneficiary \| PCs
Variable Interest Entity [Line Items]
Current assets		26,819		28,227
Current liabilities		$ 20,391		$ 13,927

Variable Interest Entities - Su

Variable Interest Entities - Summary of Deconsolidation of Joint Venture (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Apr. 01, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 300,675		$ 27,390	$ 58,819	$ 36,692
Accounts receivable, net	46,211		33,601
Prepaid expenses and other current assets	20,895		16,708
Total current assets	734,616		200,037
Other assets	4,853		8,249
Property and equipment, net	112,922		90,716
Right-of-use assets	130,554		108,046
Total assets	1,006,260		430,294
Current liabilities:
Lease liabilities, current	15,090		12,575
Other current liabilities	1,719		1,884
Total current liabilities	97,906		83,481
Lease liabilities, non-current	145,764		120,497
Total liabilities	$ 488,052		$ 211,837
Deconsolidation Joint Venture
Current assets:
Cash and cash equivalents		$ 810
Accounts receivable, net		768
Prepaid expenses and other current assets		18
Total current assets		1,596
Other assets		19
Property and equipment, net		1,504
Right-of-use assets		1,509
Total assets		4,628
Current liabilities:
Accounts payable and accrued expenses		9
Lease liabilities, current		273
Other current liabilities		143
Total current liabilities		425
Lease liabilities, non-current		1,872
Total liabilities		$ 2,297

Variable Interest Entities - As

Variable Interest Entities - Assets and Liabilities Excluding Intercompany Balances are Eliminated in Consolidated for Joint Ventures (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 300,675	$ 27,390	$ 58,819	$ 36,692
Accounts receivable, net	46,211	33,601
Prepaid expenses and other current assets	20,895	16,708
Total current assets	734,616	200,037
Other assets	4,853	8,249
Property and equipment, net	112,922	90,716
Right-of-use assets	130,554	108,046
Total assets	1,006,260	430,294
Current liabilities:
Lease liabilities, current	15,090	12,575
Other current liabilities	1,719	1,884
Total current liabilities	97,906	83,481
Lease liabilities, non-current	145,764	120,497
Total liabilities	$ 488,052	211,837
Joint Venture \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents		1,411
Accounts receivable, net		817
Prepaid expenses and other current assets		24
Total current assets		2,252
Other assets		19
Property and equipment, net		1,521
Right-of-use assets		1,553
Total assets		5,345
Current liabilities:
Accounts payable and accrued expenses		60
Lease liabilities, current		265
Other current liabilities		57
Total current liabilities		382
Lease liabilities, non-current		1,946
Total liabilities		$ 2,328

Fair Value - Schedule of Financ

Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Assets:
Assets, Fair Value	$ 363,736	$ 119,146
Liabilities:
Liabilities, Fair Value		7,220
Redeemable Convertible Preferred Stock Warrant Liability
Liabilities:
Liabilities, Fair Value		7,220
U.S. Treasury Obligations
Assets:
Assets, Fair Value	334,839	48,968
Commercial Paper
Assets:
Assets, Fair Value	28,897	70,178
Level 1
Assets:
Assets, Fair Value	334,839	48,968
Level 1 \| U.S. Treasury Obligations
Assets:
Assets, Fair Value	334,839	48,968
Level 2
Assets:
Assets, Fair Value	28,897	70,178
Level 2 \| Commercial Paper
Assets:
Assets, Fair Value	$ 28,897	70,178
Level 3
Liabilities:
Liabilities, Fair Value		7,220
Level 3 \| Redeemable Convertible Preferred Stock Warrant Liability
Liabilities:
Liabilities, Fair Value		$ 7,220

Fair Value - Additional Informa

Fair Value - Additional Information (Details) - USD ($)	Jun. 30, 2020	May 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0				$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0				0
Fair value, liabilities, level 1 to level 2 transfers, amount	0				0
Fair value, liabilities, level 2 to level 1 transfers, amount	0				0
Fair value, assets, level 1 to level 3 transfers, amount	0				0
Fair value, assets, level 3 to level 1 transfers, amount	0				0
Fair value, liabilities, level 1 to level 3 transfers, amount	0				0
Fair value, liabilities, level 3 to level 1 transfers, amount	0				0
Fair value, assets, level 2 to level 3 transfers, amount	0				0
Fair value, assets, level 3 to level 2 transfers, amount	0				0
Fair value, liabilities, level 2 to level 3 transfers, amount	0				0
Fair value, liabilities, level 3 to level 2 transfers, amount	0				$ 0
3.0% Convertible Senior Notes due 2025
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Aggregate principal amount outstanding	$ 316,250,000
Interest rate	3.00%	3.00%
Convertible Senior Notes Due 2025
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible notes fair value	$ 339,947,000
Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible redeemable preferred stock warrant liability			$ 13,740,000	$ 7,220,000

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Net revenue	$ 78,000	$ 66,233	$ 156,756	$ 129,243
Net Patient Service Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	23,927	34,882	58,013	68,428
Partnership Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	33,993	18,760	63,448	36,218
Net Patient Service and Partnership Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	57,920	53,642	121,461	104,646
Membership Revenue
Disaggregation Of Revenue [Line Items]
Net revenue	17,680	$ 12,591	32,895	$ 24,597
Grant Income
Disaggregation Of Revenue [Line Items]
Net revenue	$ 2,400		$ 2,400

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Mar. 27, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Deferred revenue			$ 15,995	$ 11,812	$ 17,458	$ 15,529
Reduction in revenue			(2,451)
Deferred revenue recognized related to variable consideration	$ 7,151
Contract with customer liability related to variable consideration non-current	$ 6,409		6,409		6,409
Health Care, Other
Disaggregation Of Revenue [Line Items]
Net revenue			20,985	29,162	50,876	57,164
Health Care, Patient Service
Disaggregation Of Revenue [Line Items]
Net revenue			2,942	$ 5,720	$ 7,137	$ 11,264
COVID-19
Disaggregation Of Revenue [Line Items]
CARES Act enacted date		Mar. 27, 2020
CARES Act \| Provider Relief Fund by HHS \| COVID-19 \| Grant Income
Disaggregation Of Revenue [Line Items]
Net revenue			$ 2,400

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Contract Assets and Deferred Revenue (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Balances from contracts with customers:
Accounts receivable	$ 46,211	$ 33,601
Contract asset (included in prepaid expenses and other current assets)	100	600
Deferred revenue	$ 43,075	$ 27,024

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Remaining Performance Obligation (Details1) $ in Thousands	Jun. 30, 2020USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation expected to be recognized	$ 20,749
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-07-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation, expected timing of satisfaction, period	6 months
Revenue remaining performance obligation expected to be recognized	$ 18,274
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue remaining performance obligation expected to be recognized	$ 2,475

Revenue Recognition - Schedul_3

Revenue Recognition - Schedule of Remaining Performance Obligation (Details) $ in Thousands	Jun. 30, 2020USD ($)
Revenue From Contract With Customer [Abstract]
Revenue remaining performance obligation expected to be recognized	$ 20,749

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities Classified as Available for Sale (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Marketable Securities [Line Items]
Amortized cost	$ 363,697	$ 119,108
Gross unrealized gains (losses)	39	38
Fair value	363,736	119,146
U.S. Treasury Obligations
Marketable Securities [Line Items]
Amortized cost	334,800	48,930
Gross unrealized gains (losses)	39	38
Fair value	334,839	48,968
Commercial Paper
Marketable Securities [Line Items]
Amortized cost	28,897	70,178
Fair value	$ 28,897	$ 70,178

Marketable Securities - Additio

Marketable Securities - Additional Information (Details)	6 Months Ended	12 Months Ended
Marketable Securities - Additional Information (Details)	Jun. 30, 2020	Dec. 31, 2019
Marketable Securities [Abstract]
Marketable securities maturity date	1 year	1 year

Property and Equipment, net - S

Property and Equipment, net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 169,310	$ 139,254
Less: Accumulated depreciation and amortization	(56,388)	(48,538)
Property and equipment, net	112,922	90,716
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	103,289	83,018
Computer Software, Including Internal-Use Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	20,586	16,508
Property and equipment, net	11,223	8,944
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	19,215	16,653
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	9,593	7,359
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,201	3,428
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 11,426	$ 12,288

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Depreciation of assets	$ 1,101	$ 733	$ 2,121	$ 1,368
Disposal of business	791	593	891	719
Property and equipment, net	112,922		112,922		$ 90,716
Depreciation and amortization expense	5,162	3,027	10,340	5,652
Software Developed for Internal Use
Property Plant And Equipment [Line Items]
Capitalized internal use software development	2,003	$ 1,558	4,399	$ 2,909
Property and equipment, net	$ 11,223		$ 11,223		$ 8,944

Leases - Additional Information

Leases - Additional Information (Details) $ in Thousands	6 Months Ended
Leases - Additional Information (Details) $ in Thousands	Jun. 30, 2020USD ($)
Lessee Lease Description [Line Items]
Operating leases, options to terminate	Certain lease agreements contain options to terminate the lease before maturity.
Operating lease, existence of option to terminate [true false]	true
Prepaid Expenses and Other Current Assets
Lessee Lease Description [Line Items]
Lease incentives to be received	$ 7,475
Maximum
Lessee Lease Description [Line Items]
Operating leases, options to extend leases term	5 years
Minimum
Lessee Lease Description [Line Items]
Operating leases, options to extend leases term	1 year

Leases - Components of Operatin

Leases - Components of Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Leases [Abstract]
Operating lease costs	$ 6,355	$ 12,315
Variable lease costs	1,013	2,029
Total lease costs	$ 7,368	$ 14,344

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 5,920	$ 11,358
Non-cash leases activity:
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$ 7,031	$ 30,638

Leases - Lease Term and Discoun

Leases - Lease Term and Discount Rate (Details)	Jun. 30, 2020
Leases [Abstract]
Weighted-average remaining lease term (in years)	8 years 7 months 6 days
Weighted-average discount rate	7.73%

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
Remainder of 2020	$ 13,339
2021	27,574
2022	26,045
2023	25,156
2024	24,746
Thereafter	108,388
Total lease payments	225,248
Less: interest	(64,394)
Total lease liabilities	$ 160,854

Debt - Additional Information (

Debt - Additional Information (Details)	1 Months Ended		3 Months Ended		6 Months Ended
Debt - Additional Information (Details)	May 31, 2020USD ($)Tradingday$ / sharesshares	Jan. 31, 2013USD ($)shares	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2019USD ($)
Debt Instrument [Line Items]
Liquidity ratio					1.50%
Fixed charge coverage ratio					1.25%
Interest expense			$ 28,000	$ 131,000	$ 78,000	$ 286,000
Debt instrument, interest rate, during period			5.60%	7.30%	6.10%	7.30%
Aggregate principal payments			$ 1,100,000	$ 1,100,000	$ 2,200,000	$ 2,200,000
3.0% Convertible Senior Notes due 2025
Debt Instrument [Line Items]
Aggregate principal payments	$ 275,000		$ 41,250,000		$ 41,250,000
Interest rate	3.00%		3.00%		3.00%
Proceeds from debt offering	$ 306,868,000
Debt instrument maturity date	Jun. 15, 2025
Debt instrument face amount	$ 1,000
Debt converted to common stock \| shares	22.5052
Debt instrument conversion price \| $ / shares	$ 44.43
Debt instrument terms of conversion feature	Holders may convert the 2025 Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined below) per $1 principal amount of the 2025 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; (3) if the Company calls such 2025 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. It is the Company’s current intent to settle conversions through combination settlement comprising of cash and equity
Debt instrument consecutive trading days \| Tradingday	30
Debt instrument, threshold trading days \| Tradingday	20
Debt instrument conversion ratio	130
Debt instrument threshold percentage of stock price	98.00%
Debt conversion due date	2025-03
Debt instrument, repurchase price percentage	100.00%
Debt issuance cost	$ 9,382,000
Issuance costs attributable to liability	7,139,000
Issuance costs attributable to equity	2,243,000
3.0% Convertible Senior Notes due 2025 \| Debt Liability Component
Debt Instrument [Line Items]
Liability component at the time of issuance date	$ 240,637,000
3.0% Convertible Senior Notes due 2025 \| Debt Equity Component
Debt Instrument [Line Items]
Interest rate	9.68%
Debt discount related to value of conversion option	$ 75,613,000
LSA
Debt Instrument [Line Items]
Maximum borrowings		$ 11,000,000
Interest rate greater of prime plus		5.56%
Number of warrants issued \| shares		494,833
LSA \| Minimum
Debt Instrument [Line Items]
Interest rate greater of prime plus		1.81%

Debt - Summary of Net Carrying

Debt - Summary of Net Carrying Amount of Liability Component of Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - Debt Liability Component $ in Thousands	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Principal	$ 316,250
Unamortized debt discount	(74,573)
Unamortized issuance costs	(7,060)
Net carrying amount	$ 234,617

Debt - Summary of Net Carryin_2

Debt - Summary of Net Carrying Amount of Equity Component of Convertible Senior Notes (Details) - Convertible Senior Notes Due 2025 - Debt Equity Component $ in Thousands	Jun. 30, 2020USD ($)
Debt Instrument [Line Items]
Debt discount related to value of conversion option	$ 75,613
Issuance costs	(2,243)
Net carrying amount	$ 73,370

Debt - Summary of Interest Expe

Debt - Summary of Interest Expense Recognized Related to Convertible Senior Notes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Debt Instrument [Line Items]
Total interest expense related to the 2025 Notes	$ 28	$ 131	$ 78	$ 286
Convertible Senior Notes Due 2025
Debt Instrument [Line Items]
Contractual interest expense	826		826
Amortization of debt discount	1,041		1,041
Amortization of issuance costs	79		79
Total interest expense related to the 2025 Notes	$ 1,946		$ 1,946

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock - Additional Information (Details) - shares	Mar. 31, 2020	Feb. 04, 2020	Dec. 31, 2019
Redeemable Convertible Preferred Stock Warrants Exercisable
Temporary Equity [Line Items]
Redeemable convertible preferred stock converted into shares of common stock	86,257,242
Series C \| Redeemable Convertible Preferred Stock Warrants Exercisable
Temporary Equity [Line Items]
Number of shares issuable			100,000
Series D \| Redeemable Convertible Preferred Stock Warrants Exercisable
Temporary Equity [Line Items]
Number of shares issuable			250,000
Series E \| Redeemable Convertible Preferred Stock Warrants Exercisable
Temporary Equity [Line Items]
Number of shares issuable			99,280
Series G \| Redeemable Convertible Preferred Stock Warrants Exercisable
Temporary Equity [Line Items]
Number of shares issuable			5,573
Number of shares outstanding			223,961
IPO
Temporary Equity [Line Items]
Redeemable convertible preferred stock converted into shares of common stock		86,257,242
IPO \| Warrants to Purchase Common Stock
Temporary Equity [Line Items]
Number of shares issuable		667,668
IPO \| Warrants to Purchase Common Stock \| Redeemable Convertible Preferred Stock Warrants Exercisable
Temporary Equity [Line Items]
Number of shares issuable	667,668

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Feb. 04, 2020	Jan. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense			$ 8,363		$ 3,390	$ 18,688	$ 6,344
Fair value of options granted			3,180		4,760	4,429	8,643
Tax benefits related to stock based awards			92		$ 178	372	$ 232
Unrecognized compensation expense related to service-based options			$ 32,690			$ 32,690
Weighted-average period over which unrecognized compensation cost is expected to be recognized			2 years 7 days
IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock issued during period, shares, new issues	20,125,000
Common stock offering price	$ 14
IPO \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock issued during period, shares, new issues				20,125,000
Secondary Offering \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock issued during period, shares, new issues						8,300,000
Common stock offering price			$ 31			$ 31
2007 Equity Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional stock awards granted						0
2017 Equity Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional stock awards granted						0
2020 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of additional stock awards granted						0
Shares available for future grants			18,604,144			18,604,144
Stock based compensation expense			$ 597			$ 1,006
2020 Employee Stock Purchase Plan \| IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance		2,800,000
Common stock available for issuance automatic increase period		10 years
Percentage of number of shares of common stock outstanding		1.50%
2020 Employee Stock Purchase Plan \| Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period						4 years
Term of options granted						10 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - 2020 Plan $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding \| shares	27,806,309
Number of Options, Granted \| shares	375,200
Number of Options, Exercised \| shares	(396,573)
Number of Options, Cancelled \| shares	(148,777)
Number of Options, Outstanding \| shares	27,636,159	27,806,309
Number of Options, Exercisable \| shares	14,862,415
Number of Options, Vested and expected to vest \| shares	24,109,807
Weighted-Average Exercise Price, Outstanding \| $ / shares	$ 5.97
Weighted-Average Exercise Price, Granted \| $ / shares	22.15
Weighted-Average Exercise Price, Exercised \| $ / shares	5.29
Weighted-Average Exercise Price, Cancelled \| $ / shares	8.69
Weighted-Average Exercise Price, Outstanding \| $ / shares	6.19	$ 5.97
Weighted-Average Exercise Price, Options exercisable \| $ / shares	4.46
Weighted-Average Exercise Price, Options vested and expected to vest \| $ / shares	$ 5.78
Weighted-Average Remaining Contractual Term (Years), Outstanding	7 years 14 days	7 years 9 months 3 days
Weighted-Average Remaining Contractual Term (Years), Options exercisable	5 years 10 months 9 days
Weighted-Average Remaining Contractual Term (Years), Options vested and expected to vest	6 years 9 months 21 days
Aggregate Intrinsic Value, Outstanding \| $	$ 832,784	$ 207,956
Aggregate Intrinsic Value, Options exercisable \| $	189,208
Aggregate Intrinsic Value, Options vested and expected to vest \| $	$ 736,237

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Detail) - 2020 Plan - Restricted Stock	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Granted \| shares	1,334,628
Number of Shares, Canceled and forfeited \| shares	(14,993)
Number of Shares, Unvested and outstanding as of March 31, 2020 \| shares	1,319,635
Grant-Date Fair Value, Granted \| $ / shares	$ 19.95
Grant-Date Fair Value, Canceled and forfeited \| $ / shares	20.79
Grant-Date Fair Value, Unvested and outstanding as of March 31, 2020 \| $ / shares	$ 19.94

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 8,363	$ 3,390	$ 18,688	$ 6,344
Sales and Marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	668	151	1,268	462
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 7,695	$ 3,239	$ 17,420	$ 5,882

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ (22)	$ 16	$ (72)	$ 26
Effective income tax rate	(0.075%)	0.137%	(0.124%)	0.141%

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Numerator:
Net loss	$ (30,301)	$ (34,557)	$ (11,488)	$ (7,044)	$ (64,858)	$ (18,532)
Less: Net loss attributable to noncontrolling interest			(287)		(704)	(661)
Net loss attributable to 1Life Healthcare, Inc. stockholders	$ (30,301)		$ (11,201)		$ (64,154)	$ (17,871)
Denominator:
Weighted average common shares outstanding — basic and diluted	126,150,347		18,365,559		105,517,206	18,285,582
Net loss per share attributable to 1Life Healthcare, Inc. stockholders — basic and diluted	$ (0.24)		$ (0.61)		$ (0.61)	$ (0.98)

Net Loss Per Share - Schedule_2

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	29,117,619	110,159,506
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	27,636,159	23,234,596
Warrants to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	161,825
Unvested Restricted Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities	1,319,635
Warrants to Purchase Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities		673,241
Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities		86,251,669

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Details) - Convertible Senior Notes Due 2025	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Earnings Per Share Basic [Line Items]
Debt converted to common stock \| shares	7,117,270
Debt instrument conversion price \| $ / shares	$ 44.43

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Sep. 30, 2018Plaintiff
Commitments And Contingencies Disclosure [Abstract]
Number of plaintiffs	1

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Related Party Transactions [Abstract]
Revenue recognized under contractual obligation	$ 155	$ 38	$ 201	$ 76
Outstanding receivable balances	$ 210		$ 210		$ 2,344